We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-6.25%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$461M
AUM Growth
+$182M
Cap. Flow
+$209M
Cap. Flow %
45.44%
Top 10 Hldgs %
74.85%
Holding
54
New
8
Increased
8
Reduced
20
Closed
12

Top Buys

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$6.76M
2
FOLD
Amicus Therapeutics
FOLD
+$5.63M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.61M
4
BCYC
Bicycle Therapeutics
BCYC
+$4.67M
5
AXSM icon
Axsome Therapeutics
AXSM
+$2.93M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$5.79M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.09M
3
CMPS
Compass Pathways
CMPS
+$4.64M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$3.89M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.83M

Sector Composition

Rank Sector Weight
1 Healthcare 43.42%
2 Financials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
51
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-55,000
Closed -$1.45M
BLU
52
DELISTED
BELLUS Health Inc.
BLU
– –
-450,000
Closed -$3.62M
BLU
53
PUT
DELISTED
BELLUS Health Inc.
BLU
– –
-891,000
Closed -$7.17M
GBT
54
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-60,000
Closed -$1.76M
1 2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Ghost Tree Capital held 54 positions worth $461M, up 65% from $279M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Ghost Tree Capital deployed $209M of net new capital in Q1 2022, opening 8 new positions and adding to 8 existing holdings. Its largest new stake was Karuna Therapeutics, Inc. Common Stock: 60,000 shares worth $7.61M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 92% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $5.79M trimmed.

  • Ghost Tree Capital's largest Q1 2022 buy was Karuna Therapeutics, Inc. Common Stock: 60,000 shares worth $7.61M.
  • Ghost Tree Capital added most to Amicus Therapeutics in Q1 2022, an estimated $5.63M increase.
  • Ghost Tree Capital's biggest Q1 2022 reduction was Ascendis Pharma A/S, cutting an estimated $5.79M.
  • Ghost Tree Capital fully exited Alnylam Pharmaceuticals in Q1 2022, selling an estimated $5.09M.
  • Ghost Tree Capital's ten largest holdings make up 75% of its $461M portfolio in Q1 2022.
  • Ghost Tree Capital opened 8 new positions and closed 12 in Q1 2022.
  • Ghost Tree Capital's portfolio value rose 65% quarter-over-quarter to $461M.

Based on Ghost Tree Capital's 13F filing for Q1 2022, filed 16 May 2022.